Aveanna Healthcare
Aveanna Healthcare's revenue rose 20.2% to $2.4 billion in fiscal 2025. Its operating margin was 10.5%, up from 6.9% a year earlier. The diluted share count rose 11.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Aveanna Healthcare does
Aveanna provides care in patients' homes for people with complex medical needs, from newborns and children to adults and seniors. Most care is given by nurses. Its patients are paid for mostly by government programs such as Medicaid and Medicare, and by private insurers.
It reports three segments. Private Duty Services is mostly private duty nursing, which means long hours of skilled nursing at home for medically complex children and young adults, plus pediatric therapy. Aveanna says it is the largest provider of this nursing in the United States. About 30% of these nursing patients are over 18. Home Health & Hospice serves mainly older people: home health care after surgery or illness, and end-of-life hospice care. Medical Solutions supplies tube-feeding formulas, equipment and respiratory supplies.
Aveanna sends bills to government programs and insurers for the care and supplies it provides. Hospitals, especially children's hospitals, send it many of its new patients. It says it competes with other home health, hospice and medical equipment companies. It grows by acquiring other home care businesses. In March 2026 it agreed to buy Family First, a pediatric home care provider with 27 locations in seven states.
Its biggest risks, as it describes them
- Competition among home health, hospice and medical equipment companies.
- Losing relationships with the hospitals and other sources that refer patients.
- Cuts or limits in government and private insurance funding, or changes to Medicare rates and rules.
- Being unable to control costs when it cannot set the rates it is paid, and shortages of nurses and other staff.
- Heavy regulation, and delays in collecting payments for its services.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 30 | 19 | 44 | 84 | 193 |
| Debt incl. finance leases | 1,236 | 1,290 | 1,286 | 1,281 | 1,300 |
| Net debt (negative means net cash) | 1,206 | 1,271 | 1,242 | 1,197 | 1,107 |
| Net debt to EBITDA | — | — | 56.8x | 8.0x | 4.1x |
| Debt to equity | 1.9x | — | — | — | 6.7x |
| Interest coverage | −0.5x | −6.0x | 0.1x | 0.9x | 1.8x |
| Current ratio | 0.8x | 0.8x | 0.9x | 1.0x | 1.3x |
| Quick ratio | 0.8x | 0.8x | 0.9x | 1.0x | 1.3x |
Cash flow
Projections
Project Aveanna Healthcare's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Aveanna Healthcare says to expect
- Full year 2026: revenue
Increased Full Year 2026 Revenue guidance to greater than $2.695 billion, updated from greater than $2.68 billion
- Full year 2026: adjusted EBITDA
Increased Full Year 2026 Adjusted EBITDA guidance to greater than $374 million, updated from greater than $365 million
Insider trades
No officer, director or 10% owner of Aveanna Healthcare reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 5 of 9 | 7 of 9 |
| Rule of 40 | — | — | — |
| Altman Z'' | −2.98 | −2.25 | −0.46 |
| Accruals ratio | −9.5% | −2.7% | 5.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 6 of 9 | 5 of 9 | 7 of 9 |
Compare
Put Aveanna Healthcare side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Aveanna Healthcare | FY25 | 20.2% | 10.5% | — | 21.6% | 4.1x | 7 | |
| Hims & Hers Health | FY25 | 59.0% | 4.5% | 2.5% | 19.0% | 2.5x | 4 | Compare |
| Chemed | FY25 | 4.1% | 13.4% | 12.9% | 27.3% | −0.2x | 5 | Compare |
| Teladoc Health | FY25 | −1.5% | −10.4% | 11.3% | −12.5% | 2.1x | 6 | Compare |
| Natera | FY25 | 35.9% | −13.4% | 4.7% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,384 | 1,495 | 1,679 | 1,788 | 1,895 | 2,024 | 2,433 |
| Revenue growth | — | 8.0% | 12.3% | 6.5% | 6.0% | 6.8% | 20.2% |
| Gross profit | 419 | 454 | 542 | 553 | 595 | 636 | 810 |
| Research and development | — | — | — | — | — | — | — |
| Operating income | 39 | −4 | −36 | −642 | 8 | 140 | 256 |
| Net income | −76 | −57 | −117 | −662 | −134 | −11 | 225 |
| Diluted EPS (US$) | −0.56 | −0.40 | −0.69 | −3.57 | −0.71 | −0.06 | 1.05 |
| Diluted shares (millions) | 137 | 141 | 171 | 186 | 190 | 193 | 215 |
| Cash flow | |||||||
| Cash from operations | −9 | 117 | −11 | −48 | 23 | 33 | 126 |
| Capital expenditure | 17 | 15 | 16 | — | — | — | — |
| Free cash flow | −25 | 101 | −27 | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 1 | 178 | 667 | 2 | 0 | 0 | 15 |
| Stock-based compensation | 2 | 3 | 14 | 16 | 13 | 18 | 25 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | — | 137 | 30 | 19 | 44 | 84 | 193 |
| Debt incl. finance leases | — | 1,176 | 1,236 | 1,290 | 1,286 | 1,281 | 1,300 |
| Total assets | — | 1,844 | 2,334 | 1,712 | 1,613 | 1,663 | 2,012 |
| Total liabilities | — | 1,577 | 1,696 | 1,716 | 1,740 | 1,786 | 1,817 |
| Shareholders' equity | 270 | 265 | 636 | −6 | −130 | −124 | 194 |
| Margins and ratios | |||||||
| Gross margin | 30.3% | 30.4% | 32.3% | 30.9% | 31.4% | 31.4% | 33.3% |
| Operating margin | 2.8% | −0.2% | −2.1% | −35.9% | 0.4% | 6.9% | 10.5% |
| Net margin | −5.5% | −3.8% | −7.0% | −37.0% | −7.1% | −0.5% | 9.2% |
| Free cash flow margin | −1.8% | 6.8% | −1.6% | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | 14.8% | 10.7% | — | — | — | — |
| Return on capital | — | — | −1.8% | −32.7% | 0.5% | 6.4% | 21.6% |
| Return on equity | — | — | −26.0% | −210.3% | — | — | — |
| Return on assets | — | — | −5.6% | −32.7% | −8.1% | −0.7% | 12.2% |
| Net debt to EBITDA | — | 76.7x | — | — | 56.8x | 8.0x | 4.1x |